Corbus Pharmaceuticals Holdings, Inc. (CRBP)
| Market Cap | 32.35M |
| Revenue (ttm) | 233,881 |
| Net Income (ttm) | -39.01M |
| Shares Out | 125.26M |
| EPS (ttm) | -0.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 207,227 |
| Open | 0.277 |
| Previous Close | 0.252 |
| Day's Range | 0.256 - 0.277 |
| 52-Week Range | 0.208 - 1.790 |
| Beta | 2.03 |
| Analysts | Buy |
| Price Target | 2.02 (+682.0%) |
| Earnings Date | Aug 11, 2022 |
About CRBP
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks t... [Read more...]
Financial Performance
In 2021, CRBP's revenue was $881,705, a decrease of -77.61% compared to the previous year's $3.94 million. Losses were -$45.64 million, -58.98% less than in 2020.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CRBP stock is "Buy." The 12-month stock price forecast is 2.02, which is an increase of 682.04% from the latest price.
News
Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunothe...
CRB-601 is a highly potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of TGF b in the local tumor microenvironment Additional non-clinical data demonstrates co...
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission for CRB-601 is on-track for the first half of 2023 Ex...
Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting
NORWOOD, Mass. , April 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced today the first preclinical data for CRB...
Hot Marijuana Penny Stocks Under $1 To Watch Ahead Of MORE Act Vote
Marijuana penny stocks to watch right now. The post Hot Marijuana Penny Stocks Under $1 To Watch Ahead Of MORE Act Vote appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
Want to try an out-of-the-box approach? Tap five stocks including CRI, TH, IQ, BKE and CRBP with increasing P/E ratios.
Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
NORWOOD, Mass., March 11, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announcing that Yuval Cohen, Ph.D.
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates
NORWOOD, Mass., March 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported finan...
After Plunging 29.4% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
The heavy selling pressure might have exhausted for Corbus Pharmaceuticals (CRBP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree...
Down 31.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earning...
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
NORWOOD, Mass., Dec. 7, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company") today announced the appointment of Rachael Brake, Ph.D.
Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
NORWOOD, Mass., Nov. 12, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided corporate updates and reported finan...
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
NORWOOD, Mass., Nov. 11, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announced that Yuval Cohen, Ph.D.
Will Corbus Pharmaceuticals (CRBP) Report Negative Q3 Earnings? What You Should Know
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -25.00% and -83.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Corbus Pharmaceuticals Q2 Earnings
Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 71.15% year over year to ($0.15)...
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
Norwood, MA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today provided corporate updates and reported fina...
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist
Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Informat...
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomy...
Norwood, MA, June 24, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicines that target inflamm...
3 Biotech Stocks With Big Catalysts in June
Important events on the horizon could push these biotech stocks higher or press them further into the dirt.
Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
This Biotech Penny Stock Is Better Than Dogecoin
You might want to avoid buying it, though.
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
Norwood, MA, June 01, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced licensing deals for two new monoclonal antibodies (mAbs),...
3 Biotech Penny Stocks That Are Popular on Reddit Right Now
Looking for biotech penny stocks on Reddit? Check these 3 out for your watchlist The post 3 Biotech Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News a...